1. NSCIF achieved record Q4 revenue of $12.3MM, a 25% rise. 2. Annual revenue reached $45MM, marking a 60% growth year-over-year. 3. Adjusted EBITDA was $1.8MM with significant operational improvements. 4. Company anticipates some sales pressure due to tariff uncertainties. 5. CEO emphasizes focus on profitable growth and innovation.
The strong revenue growth indicates robust market interest, akin to past surges in technological stocks during earnings seasons, leading to subsequent price increases.
High revenue growth and improved financial metrics assert the company's market position and potential, attracting investor interest and influencing stock price.
Quarterly results and positive EBITDA can lead to immediate investor interest, but future sales pressure may temper long-term optimism.
CALGARY, AB, April 24, 2025 /PRNewswire/ -
Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, announces fourth quarter and full year results for the period ending on December 31, 2024, achieving 25% year-over-year revenue growth to $12.3 million in the fourth quarter of 2024 and 60% revenue growth over the prior year to $45 million for the full year ended December 31, 2024. Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Randall McRae will host a conference call at 5 P.M. Eastern Time today to discuss the results. A second call will be held for European investors at 8:30 A.M. Eastern Time tomorrow, Friday, April 25th. All interested parties are invited to join these calls. All dollar figures in this press release are in thousands of Canadian dollars, except per share amounts or unless otherwise stated.
"We are very proud of our results for both the fourth quarter and the full year," said Sean Krakiwsky, Founder and CEO of Nanalysis. "Our revenue growth is attributed to expansion in both of our core business segments, product sales and security services. This is the culmination of the work and focus we have put into our sales organization that brings our best-in-class Benchtop NMR products to market, with higher average selling prices, and bolstered by ongoing innovation. Additionally, our team has been able to concentrate on operational excellence in building a world class service organisation with coverage from coast to coast. In doing so, we have been able to drive efficiencies in both our manufacturing processes and service delivery which resulted in improved gross margins and positive Adjusted EBITDA. We plan to continue on this path to profitable growth, as a fully vertically integrated scientific instrumentation and service company."
| Three months ended December 31 ($000's) | 2024 | 2023 | Change | Change % |
|---|---|---|---|---|
| Product sales | 5,536 | 5,450 | 86 | 2 % |
| Security services revenue | 5,602 | 3,362 | 2,240 | 67 % |
| Flow-through inventory revenue | 1,151 | 988 | 163 | 16 % |
| Total sales and revenue | 12,289 | 9,800 | 2,489 | 25 % |
| Adjusted EBITDA | 1,835 | (677) | 2,512 | - |
"Since we went public in 2019 we've quintupled revenue and the company is Adjusted EBITDA and operating cash-flow positive. We've spent the last two years executing a strategy combining growth with generating positive operating cash-flow," continued Mr. Krakiwsky.
"Like all exporters with global supply chains, we are not immune from global sentiment and have encountered some feelings of uncertainty with some of our U.S. customers regarding tariffs. In response we have taken certain specific measures to mitigate risks associated with tariffs and export controls on key products. Thus far, our mitigation efforts have succeeded, but we do expect some downward pressure on product sales for the first half of 2025. That being said, our sales funnel is robust and we will remain vigilant on these matters as the landscape evolves."
The Company announces that René Lenggenhager has resigned from the Board of Directors. The Company thanks him for his service and wishes him well.
Investors interested in participating in the live full year call can dial 1-800-510-2154 or 437-900-0527 from abroad. Investors can also access the call online through a listen-only webcast here on the investor relations section of the Company's website.
Nanalysis Scientific Corp. operates two primary business segments: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, except as expressly required by applicable law.